These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 12949537)

  • 1. Ownership at too high a price?
    Nat Biotechnol; 2003 Sep; 21(9):953. PubMed ID: 12949537
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechs sue Columbia over fourth Axel patent.
    Howard K
    Nat Biotechnol; 2003 Sep; 21(9):955-6. PubMed ID: 12949538
    [No Abstract]   [Full Text] [Related]  

  • 3. US court case to define EST patentability.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):513. PubMed ID: 15877055
    [No Abstract]   [Full Text] [Related]  

  • 4. Napster case spills into biotech sector.
    Bouchie A
    Nat Biotechnol; 2004 Sep; 22(9):1185-6. PubMed ID: 15384189
    [No Abstract]   [Full Text] [Related]  

  • 5. Equivalents in biotechnology patents.
    Auer HE
    Nat Biotechnol; 2003 Mar; 21(3):329-31. PubMed ID: 12610574
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotechnology patents under fire.
    Royzman I
    Nat Biotechnol; 2015 Sep; 33(9):925-6. PubMed ID: 26348959
    [No Abstract]   [Full Text] [Related]  

  • 7. Patenting the parts.
    Nat Biotechnol; 2007 Aug; 25(8):822. PubMed ID: 17687343
    [No Abstract]   [Full Text] [Related]  

  • 8. The importance of getting inventorship right.
    Sheiness D; Canady K
    Nat Biotechnol; 2006 Feb; 24(2):153-4. PubMed ID: 16465154
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the viability of the Lilly doctrine on the decline?
    Walker BW; Carty SM
    Nat Biotechnol; 2003 Aug; 21(8):943-4. PubMed ID: 12894207
    [No Abstract]   [Full Text] [Related]  

  • 10. Determining the meaning of claim terms.
    Auer HE
    Nat Biotechnol; 2006 Jan; 24(1):41-3. PubMed ID: 16404391
    [No Abstract]   [Full Text] [Related]  

  • 11. The 'Lilly doctrine' is viable and critical.
    Caltrider SP; Kelley JJ
    Nat Biotechnol; 2003 Oct; 21(10):1131-2. PubMed ID: 14520388
    [No Abstract]   [Full Text] [Related]  

  • 12. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 13. The coming US patent opposition.
    Apple T
    Nat Biotechnol; 2005 Feb; 23(2):245-7. PubMed ID: 15696151
    [No Abstract]   [Full Text] [Related]  

  • 14. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 15. Brand: a company's most valuable asset.
    Carter S
    Med Device Technol; 2004 Jun; 15(5):11. PubMed ID: 15285479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patenting pieces of people.
    Nat Biotechnol; 2003 Apr; 21(4):341. PubMed ID: 12665804
    [No Abstract]   [Full Text] [Related]  

  • 17. No room for experiment: the Federal Circuit's narrow construction of the experimental use defense.
    Ludwig SP; Chumney JC
    Nat Biotechnol; 2003 Apr; 21(4):453. PubMed ID: 12665827
    [No Abstract]   [Full Text] [Related]  

  • 18. Protecting innovation in biotechnology startups.
    Steffe EK; Shea TJ
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE51-3. PubMed ID: 12874982
    [No Abstract]   [Full Text] [Related]  

  • 19. Affymetrix in new patents row.
    Ledford H
    Nature; 2008 Jul; 454(7203):377. PubMed ID: 18650873
    [No Abstract]   [Full Text] [Related]  

  • 20. Patenting pluripotence: the next battle for stem cell intellectual property.
    Vrtovec KT; Scott CT
    Nat Biotechnol; 2008 Apr; 26(4):393-5. PubMed ID: 18392018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.